Table 2.
Rate of HPV DNA detection in subjects with and without cutaneous SCC
| Genus | Cases
|
Controls
|
ORs (95% CI)
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| Lesion (n=85) no. (%) | Perilesion (n=72) no. (%) | Sun (n=95) no. (%) | No sun (n=95) no. (%) | Lesion versus perilesion1 | Lesion versus sun2 | Lesion versus no sun2 | Perilesion versus sun2 | Perilesion versus no sun2 | |
| All genuses | 46 (54%) | 36 (50%) | 56 (59%) | 47 (49%) | 1.2 (0.6–2.6) | 0.9 (0.4–1.8) | 1.2 (0.6–2.5) | 0.6 (0.3–1.3) | 0.9 (0.4–1.8) |
|
| |||||||||
| α-Papillomavirus | |||||||||
| All α-papillomavirus | 7 (8%) | 7 (10%) | 3 (3%) | 4 (4%) | 0.7 (0.2–2.4) | 3.0 (0.6–14.3) | 1.9 (0.4–7.9) | 3.4 (0.6–18.3) | 2.0 (0.4–9.4) |
| 9 | 2 (2%) | 2 (3%) | 0 (0%) | 0 (0%) | 1.0 (0.1–7.1) | — | — | — | — |
| 10 | 3 (4%) | 6 (8%) | 2 (2%) | 2 (2%) | 0.2 (0.02–1.7) | 1.6 (0.2–14.2) | 0.8 (0.1–6.9) | 3.2 (0.4–22.4) | 1.8 (0.3–12.3) |
|
| |||||||||
| β-Papillomavirus | |||||||||
| All β-papillomavirus | 42 (49%) | 32 (44%) | 51 (54%) | 43 (45%) | 1.3 (0.6–2.7) | 1.0 (0.5–2.0) | 1.3 (0.6–2.5) | 0.7 (0.3–1.5) | 0.9 (0.4–1.8) |
| 1 | 24 (28%) | 25 (35%) | 29 (31%) | 24 (25%) | 0.7 (0.3–1.5) | 1.3 (0.6–2.7) | 1.3 (0.6–2.8) | 1.3 (0.6–2.8) | 1.3 (0.6–2.8) |
| 2 | 29 (34%) | 12 (17%) | 28 (29%) | 23 (24%) | 4.0 (1.3–12.0) | 1.3 (0.6–2.7) | 1.7 (0.8–3.6) | 0.5 (0.2–1.2) | 0.6 (0.3–1.5) |
| 3 | 3 (4%) | 1 (1%) | 6 (6%) | 4 (4%) | 2.0 (0.2–22.1) | 1.6 (0.3–7.4) | 2.7 (0.5–14.3) | 0.5 (0.1–5.1) | 0.9 (0.1–9.2) |
|
| |||||||||
| γ-Papillomavirus | |||||||||
| All γ-papillomavirus | 7 (8%) | 4 (6%) | 7 (7%) | 3 (3%) | 1.5 (0.4–5.3) | 1.0 (0.3–3.2) | 2.2 (0.5–9.7) | 0.6 (0.1–2.8) | 1.7 (0.3–9.3) |
| 3 | 3 (4%) | 4 (6%) | 2 (2%) | 2 (2%) | 0.8 (0.2–3.4) | 2.1 (0.3–15.3) | 1.7 (0.3–11.4) | 3.0 (0.4–21.2) | 2.6 (0.4–16.8) |
CI, confidence interval; HPV, human papillomavirus; OR, odds ratio; SCC, squamous cell carcinoma.
1
Paired analysis (n=72) comparing HPV detection in lesions to perilesion in cases.
2
Adjusted for propensity to sunburn.